BBI Ph1 TP-3654 and Ruxolitinb in patients with Intermediate and High Risk Myelofibrosis
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Sumitomo Dainippon Pharma Co.
Start Date
February 28, 2020
End Date
March 31, 2025
Administered By
Duke Cancer Institute
Awarded By
Sumitomo Dainippon Pharma Co.
Start Date
February 28, 2020
End Date
March 31, 2025